ライフサイエンスコーパス: efficacy against

1 The primary endpoint was vaccine efficacy against 6-month persistent infection or cervica

2 The primary endpoint was vaccine efficacy against 6-month persistent infection or cervica

3 ing-to-protocol cohort for efficacy, vaccine efficacy against 6-month persistent infection or CIN1+ a

4 o noted significant cross-protective vaccine efficacy against 6-month persistent infection with HPV 3

5 We also noted significant cross-protective efficacy against 6-month persistent infection with HPV 3

6 with the best compound (6p) retaining better efficacy against a broad panel of known INSTI resistant

7 accination showed protective and therapeutic efficacy against a clinically relevant allergen Bla g 1.

8 hibited moderate clearance in dog, promising efficacy against a MRSA strain in a mouse infection mode

9 the bioactive form of CPT and show in vitro efficacy against a number of cancer cell lines.

10 oA reductase) by statins has shown potential efficacy against a number of cancers.

11 Here we demonstrate its efficacy against a pandemic H1N1 challenge virus in the

12 eir inherent immunogenicity and demonstrated efficacy against a poorly immunogenic tumour, make CPMV

13 l of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to t

14 t the guanidinium compound showed the higher efficacy against a strain with N2 subtype at a concentra

15 e CD19-specific CAR to investigate antitumor efficacy against a syngeneic B cell lymphoma cell line w

16 4-CD8 lipopeptide vaccine and the protective efficacy against acute virus replication and ocular dise

17 2-p53-binding interphase, and have low or no efficacy against advanced breast cancer with mutant or d

18 This is the first demonstration of vaccine efficacy against aerosol challenge with virulent type A

19 ate vaccine strains showed strong protective efficacy against AHSV infection in an IFNAR(-/-) mouse m

20 ng ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB.

21 ALK inhibitors have shown systemic efficacy against ALK-rearranged NSCLC in many clinical t

22 The primary endpoint was protective efficacy against all episodes of clinical malaria at 2-1

23 Vaccine efficacy against all malaria episodes, vaccine efficacy

24 promising next-generation vaccine with broad efficacy against all relevant mucosal and also cutaneous

25 ree arenaviruses and demonstrated protective efficacy against all three targets.

26 AChE inhibitors, agents that have shown high efficacy against Alzheimer's disease, by detecting dual-

27 FMP2.1/AS02(A) had the highest efficacy against AMA1 alleles that were identical to the

28 ting CD44, CD123, and CD47 have demonstrated efficacy against AML LSC in xenotransplantation models.

29 nvestigate if Truvada maintains prophylactic efficacy against an FTC-resistant isolate containing the

30 how that Truvada maintains high prophylactic efficacy against an FTC-resistant isolate.

31 Direct intratumoral injection of cps has efficacy against an inducible genetic melanoma model and

32 No regimen had any protective efficacy against anaemia or hospital admission.

33 tocol efficacy population; the corresponding efficacies against anal intraepithelial neoplasia associ

34 In the restricted cohort, vaccine efficacy against anal HPV 16/18 infection was 83.6% (66.

35 ded anal specimens for assessment of vaccine efficacy against anal HPV 16/18 infection.

36 17-AAG, especially when combined, also show efficacy against aneuploid human cancer cell lines.

37 ely to engender resistance, will likely have efficacy against antibiotic-resistant strains, and may h

38 The observed vaccine efficacy against asymptomatic dengue virus infections is

39 Vaccine efficacy against atypical squamous cells of undetermined

40 tioning by effector T cells, thus broadening efficacy against autoimmunity.

41 These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identi

42 this activity was consistent with selective efficacy against Ba/F3 cells expressing BCR-ABL (IC(50):

43 -approved drugs for off-label broad-spectrum efficacy against Bacillus anthracis; Francisella tularen

44 alone has generated demonstrable high-level efficacy against blood-stage infection in clinical trial

45 ell responses are associated with protective efficacy against blood-stage malaria, whereas CD8(+) T c

46 Fragments retained efficacy against both soluble and tethered ligands with

47 Absolute efficacy against both types of influenza, as measured by

48 ody to PMA-FLA showed evidence of protective efficacy against both types of this organism in a mouse

49 hat control systemic disease have diminished efficacy against brain lesions.

50 nant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate c

51 the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and ot

52 In the present study, BKIs were screened for efficacy against C. parvum infection in the neonatal mou

53 specific IgE antibodies might offer improved efficacy against cancer by recruiting key immune effecto

54 e their aqueous properties and enhance their efficacy against cancer cells in vitro.

55 , a novel antifungal polyketide with in vivo efficacy against Candida albicans, was discovered using

56 USION Inotuzumab ozogamicin has demonstrated efficacy against CD22(+) B-cell NHL, with reversible thr

57 cate that VSV-gp160G exerts potent oncolytic efficacy against CD4(+) malignant cells and either alone

58 Both treatments showed similar efficacy against ceftazidime-nonsusceptible pathogens.

59 spectively) and similar to the regimen's own efficacy against ceftazidime-susceptible infections (82.

60 testing novel HIV prevention strategies for efficacy against cell-associated HIV transmission.

61 pe 1 (HIV-1) are evaluated preclinically for efficacy against cell-free viral challenges.

62 maximum neutralization capacity or in vitro efficacy against cell-to-cell infection of HIV-1 with T/

63 Sunitinib has shown efficacy against certain imatinib-resistant mutants, alt

64 6% (66.7-92.8), which was similar to vaccine efficacy against cervical HPV 16/18 infection (87.9%, 77

65 Vaccine efficacy against cervical HPV 16/18 infection in the sam

66 lso induced significantly greater protective efficacy against challenge with virulent S. pneumoniae.

67 We used a PSAC inhibitor with different efficacies against channels from two Plasmodium falcipar

68 conjugate vaccines (PCVs) have demonstrated efficacy against childhood pneumococcal disease in sever

69 emory responses are likely to show augmented efficacy against chronic challenges like tumor.

70 In the total vaccinated cohort, vaccine efficacy against CIN1+ irrespective of HPV was significa

71 Vaccine efficacy against CIN2+ associated with the composite of

72 In the most conservative analysis of vaccine efficacy against CIN2+, where all cases co-infected with

73 100 is the first therapeutic vaccine to show efficacy against CIN2/3 associated with HPV-16 and HPV-1

74 We used this panel to predict antibody efficacy against circulating HCV strains, highlighting t

75 modium falciparum and has partial protective efficacy against clinical and severe malaria disease in

76 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria.

77 oite antibody titres predict the duration of efficacy against clinical malaria across different age c

78 f Plasmodium falciparum, had allele-specific efficacy against clinical malaria in a phase II trial in

79 ffords in the neighborhood of 50% protective efficacy against clinical malaria is in the late stages

80 pecific targeted therapies, which could have efficacy against CLL cells that rely on specific biologi

81 Safety and efficacy against coinfections with soil-transmitted helm

82 Studies of pneumococcal vaccine efficacy against colonization have been proposed as a no

83 he closely related receptor ERBB2 has modest efficacy against colorectal cancers in the clinic.

84 oietic malignancies, most have shown limited efficacy against complex solid tumors.

85 ASAQ exhibited high efficacy against CQ resistant P. vivax and is an adequat

86 ort and long CARs targeting TSLPR and tested efficacy against CRLF2-overexpressing B-ALL.

87 cy was 55.4% (95% CI, 39.1 to 67.3), and the efficacy against culture-confirmed influenza 55.9% (97.5

88 onfidence interval [CI], 45.2 to 69.7), with efficacy against culture-confirmed influenza of 59.1% (9

89 r polyamine metabolism has shown exceptional efficacy against cutaneous squamous cell carcinomas (SCC

90 ssess household water treatment (HWT) device efficacy against diarrheal disease in developing countri

91 esults complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16

92 conserved region of the M protein has shown efficacy against disease that follows i.p. inoculation o

93 en extensively characterized and shows broad efficacy against divergent H1N1 strains in the mouse mod

94 Both chemicals have similar mechanistic efficacy against DNA mismatch repair-proficient tumor ce

95 Covering spills decreased disinfection efficacy against E. coli on heavy-duty tarp but does pre

96 LY3023414 demonstrates efficacy against EAC in a preclinical model, establishin

97 otable achievement, its long-term protective efficacy against each of the 4 dengue virus serotypes re

98 dy responses and further improved protective efficacy against Ebola virus infection.

99 OV and so far the only vaccine with reported efficacy against EBOV infections in humans in phase III

100 ptide synthesis, rapid proteolysis, and poor efficacy against emerging drug-resistant strains.

101 (s) alone has induced significant protective efficacy against erythrocytic-stage infection in a pre-s

102 he hydroalcoholic extract showed the highest efficacy against Escherichia coli.

103 ynthesized and evaluated for antileishmanial efficacy against experimental visceral leishmaniasis (VL

104 the circumsporozoite protein had on vaccine efficacy against first episodes of clinical malaria with

105 lex fungal metabolite that exhibits systemic efficacy against fleas via modulation of an invertebrate

106 vely removes bacteria from surfaces, but its efficacy against fungi has not been fully tested.

107 a bovine genetic backbone, the high vaccine efficacy against G8 strains might be partially explained

108 HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negat

109 hemotherapy drug for GBM increased antitumor efficacy against glioblastoma in experimental animals.

110 A kinase inhibitor alisertib exhibits potent efficacy against glioblastoma neurosphere tumor stem-lik

111 ies of these molecules, derived from in vivo efficacy against Gram-positive and Gram-negative pathoge

112 human H2 influenza viruses, but the in vivo efficacy against H2 viruses is unknown.

113 rated superior immunogenicity and protective efficacy against H7N9 infection in ferrets and hold pote

114 otential targets to improve chemotherapeutic efficacies against HCC.

115 yet highly enhanced photodynamic inhibition efficacy against Hela cells under a broad spectrum of li

116 Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence

117 It induces sterile protective efficacy against heterologous strain sporozoites in thre

118 against tumor necrosis factor alpha, showed efficacy against hidradenitis suppurativa.

119 ccine with a viral-vectored component showed efficacy against HIV infection in humans.

120 cine approach shown to elicit any protective efficacy against HIV-1 acquisition is based on a poxviru

121 the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1 acquisition.

122 A recent vaccine regimen has shown modest efficacy against HIV-1 acquisition.

123 The RV144 trial was the first to show efficacy against HIV-1 infection.

124 duced by the RV144 vaccine may have improved efficacy against HIV-1 infection.

125 vo yet retains immunogenicity and protection efficacy against homologous and heterologous influenza v

126 ace of the VSV glycoprotein, have shown 100% efficacy against homologous filovirus challenge in roden

127 on particle) for safety, immunogenicity, and efficacy against homologous ID challenge with O. tsutsug

128 Oxantel pamoate had low efficacy against hookworm and A. lumbricoides.

129 Vaccine efficacy against hospitalization for dengue was 80.3%.

130 dels incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical c

131 Vaccine efficacy against HPV 16/18-related 6-month persistent in

132 Vaccine efficacy against HPV 16/18-related cytological abnormali

133 Vaccine efficacy against HPV-31/33/45 for two-dose women who rec

134 Assuming 95% efficacy against HPV16 and HPV18 infections, the direct

135 his study, we report that gD/AS04 has higher efficacy against HSV-1 compared to HSV-2 genital herpes

136 However, efficacy against HSV-1 genital disease was 58% (95% CI,

137 Vaccine efficacy against HSV-1 infection (with or without diseas

138 out disease) was 35% (95% CI, 13 to 52), but efficacy against HSV-2 infection was not observed (-8%;

139 family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic c

140 AC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acqu

141 served that 18a displayed potent therapeutic efficacy against human lung adenocarcinoma A549 and colo

142 antly, BXI-61 and BXI-72 exhibit more potent efficacy against human lung cancer than ABT-737 but less

143 pounds exhibited modest, though significant, efficacy against human tumor lines and patient-derived x

144 wer systemic toxicity and higher therapeutic efficacy against i.p. chemotherapy-resistant uterine ser

145 tory approaches that continue to demonstrate efficacy against immune associated diseases.

146 Vaccine efficacy against incident HPV-16/18 infection for two-do

147 We assessed vaccine efficacy against incident HPV-16/18 infection in the mod

148 Vaccine efficacy against incident HPV-16/18 infections for three

149 Vaccine efficacy against incident HPV-31/33/45 infections for th

150 uman papillomavirus (HPV) vaccines have high efficacy against incident infection and disease caused b

151 Vaccine efficacy against incident zoster and PHN has been demons

152 type of CD8(+) T cells may determine vaccine efficacy against infection by MARV Angola.

153 +) T cells was estimated to increase vaccine efficacy against infection to 40% (95% CI, 34%-48%).

154 or sofosbuvir and velpatasvir had decreased efficacy against infection with the DBN3a sofosbuvir esc

155 Hits from the screen were validated by efficacy against infectious rabies virus in mammalian ce

156 broad-spectrum antiviral drug Arbidol shows efficacy against influenza viruses by targeting the hema

157 iple receptors, displaying anti-inflammatory efficacy against innate immune responses in the airway.

158 , 5F6, and 7A9, and determined their in vivo efficacies against intranasal challenge with WU2, a sero

159 ted whether macrophages are required for 1E2 efficacy against intranasal infection with ST3 and found

160 the mutant to evaluate safety and protective efficacy against intraperitoneal and aerosol challenge.

161 nuating diarrhea and in providing protective efficacy against intraperitoneal Shigella infection.

162 The essential oil showed mutagen-protective efficacy against IQ and MeIQ tested as direct mutagens (

163 ith Torin2 in vivo did not yield significant efficacy against KRAS-driven lung tumors, but the combin

164 e assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza in infan

165 ve led to new immunotherapeutics with proven efficacy against late-stage cancers.

166 immune responses and thereby enhance vaccine efficacy against leishmaniasis.

167 In the per-protocol population, efficacy against lesions related to HPV-6, 11, 16, or 18

168 e with vaccination showed greater protective efficacy against lethal challenge, as evidenced by no lo

169 th GP and sGP DNA vaccines in mice and their efficacy against lethal Ebola virus challenge.

170 targeting this site show potent therapeutic efficacy against lethal EBOV challenge in mice.

171 g opsonophagocytic assays and for protective efficacy against lethal peritonitis in mice.

172 f chronic myeloid leukemia (CML) has limited efficacy against leukemia stem cells (LSC) responsible f

173 ncer stem cells and help advance therapeutic efficacy against lung cancers.

174 However, we detected no efficacy against M tuberculosis infection or disease, al

175 , the immune responses necessary for vaccine efficacy against M. tuberculosis have not been defined.

176 ine approach could induce long-lived vaccine efficacy against M. tuberculosis in C57BL/6 mice.

177 mma and TNF is not a requirement for vaccine efficacy against M. tuberculosis, despite these cytokine

178 Protective efficacy against malaria, compared with daily proguanil,

179 Upon testing in vivo in a murine model of efficacy against malaria, high levels of compound exposu

180 halitis virus (VEEV) demonstrated protective efficacy against Marburg virus in nonhuman primates.

181 Vaccine efficacy against matching strains was consistently high

182 whose potent antibacterial activity, in vivo efficacy against MDR A. baumannii infections and promisi

183 producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects.

184 Akt inhibitor with demonstrated preclinical efficacy against melanoma and colon cancer.

185 at vitamin D intake may have chemopreventive efficacy against melanoma, but there have been no publis

186 an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.

187 tion, we identify TLM analogues with in vivo efficacy against MRSA and Klebsiella pneumoniae in anima

188 e findings demonstrate that NDV-3 protective efficacy against MRSA in SSSI involves a robust and comp

189 al combination agents to restore beta-lactam efficacy against MRSA.

190 insights into the mechanism of ceftobiprole efficacy against MRSA.

191 gents exhibit in vitro activity and clinical efficacy against MRSA.

192 ntibiotic activity, including broad-spectrum efficacy against multidrug resistant enterococci and Sta

193 eed relatively high colistin daily doses for efficacy against multidrug-resistant and extensively dru

194 J379 and BC035) by profiling their antiviral efficacy against multidrug-resistant influenza A viruses

195 need for therapeutics with broad protective efficacy against multiple filoviruses.

196 s with improved drug kinetics and multistage efficacy against multiple human parasites.

197 ins have been shown to possess antimicrobial efficacy against multiple species of bacteria including

198 highly selective ELQs with outstanding oral efficacy against murine malaria that is superior to esta

199 terium bovis challenge in animal models, for efficacy against Mycobacterium leprae challenge in a mur

200 ary outcomes were immunogenicity and vaccine efficacy against Mycobacterium tuberculosis infection an

201 colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB).

202 analysis evaluates cross-protective vaccine efficacy against non-vaccine oncogenic HPV types in the

203 Secondary analyses included vaccine efficacy against non-vaccine oncogenic HPV types.

204 an M1, response may further improve vaccine efficacy against ocular HSV-1 replication and latency.

205 e HPV-16/18 endpoint), we calculated vaccine efficacy against one-time detection of incident HPV infe

206 easing in incidence among males, and vaccine efficacy against oral HPV infections in men has not been

207 NS5A inhibitors had varying levels of efficacy against original and resistant viruses.

208 armacokinetic profile, and demonstrates good efficacy against osteoarthritis pain in rodents.

209 liver and kidney tumors, and also has shown efficacy against other malignancies.

210 Here we show that lack of efficacy against P. berghei in mice resulted from a comb

211 ith RIG-I signaling confers potent antitumor efficacy against pancreatic cancer by breaking tumor-ind

212 cine-induced immune responses and protective efficacy against pandemic H1N1 influenza virus.

213 and spectrum, as well as examples of in vivo efficacy against pathogens including Staphylococcus aure

214 The vaccine's efficacy against PCR-confirmed influenza illness and the

215 The vaccine's efficacy against PCR-confirmed influenza illness was hig

216 the linezolid AUC0-24/MIC target for optimal efficacy against pediatric intracellular tuberculosis, a

217 ed trial that was designed to assess vaccine efficacy against persistent cervical HPV 16/18 infection

218 Consistent vaccine efficacy against persistent infection and CIN2+ (with or

219 -adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of

220 tion demonstrated the greatest antimicrobial efficacies against planktonic or biofilm bacteria.

221 t pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumon

222 om highly transcribed C1A, and evaluated its efficacy against pretreated corn stover and switchgrass.

223 In the full cohort, vaccine efficacy against prevalent HPV 16/18 infection measured

224 in inhibition in vivo significantly enhanced efficacy against primary and metastatic tumors, supporti

225 e that a candidate P. vivax vaccine with low efficacy against primary infection may substantially red

226 identified stable differences in furosemide efficacy against PSAC activity induced by HB3 and 3D7A p

227 and release free PTX after cell entry, shows efficacy against PTX-resistant ovarian cancer cells.

228 iations of trial setting and design with BCG efficacy against pulmonary and miliary or meningeal tube

229 survivin with SA-4-1BBL/MPL yielded superior efficacy against pulmonary metastases.

230 In this study, we determined whether 1E2 efficacy against pulmonary ST3 infection requires Fcgamm

231 Univariable meta-regression indicated efficacy against pulmonary tuberculosis varied according

232 on" INSTIs are needed that will have greater efficacy against RAL- and EVG-resistant strains of IN.

233 DAC were evaluated for in vitro and in vivo efficacy against RCC cell lines, including a p53-mutated

234 tors to develop compounds that have improved efficacies against recombinant IN in biochemical assays.

235 ll quantity and quality determine protective efficacy against reinfection.

236 strains is greater than 30% and the relative efficacy against resistant strains is greater than 0.2 b

237 in per dose) to compare the relative vaccine efficacy against reverse-transcriptase polymerase-chain-

238 ts that modifications to RMP may recover its efficacy against RIF(R) TB.

239 fully optimized regimen), and increasing the efficacy against RR TB from 76% to 94% lowered RR TB mor

240 ivity and in vivo protective and therapeutic efficacy against RSV.

241 mproved vector immunogenicity and protective efficacy against RSV.

242 jugates were screened for their photodynamic efficacy against several cancer cell lines expressing di

243 activity against HUVEC cells and anticancer efficacy against several cancer cell lines.

244 mber of potent antivirals with submicromolar efficacy against several human clinical isolates of infl

245 Vaccine efficacy against severe malaria was 26.0% (95% CI, -7.4

246 ficacy against all malaria episodes, vaccine efficacy against severe malaria, safety, and immunogenic

247 Two new rotavirus vaccines have shown efficacy against severe rotavirus disease in large clini

248 years in those in the placebo group; vaccine efficacy against severe rotavirus gastroenteritis was 53

249 We compared the relative efficacies against simian immunodeficiency virus (SIV) c

250 distribution to liver, and increased in vivo efficacy against single or multiple targets with a singl

251 pies that induce T-cell responses have shown efficacy against some solid malignancies in patients and

252 Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined

253 d lethal pneumonia, providing broad-spectrum efficacy against staphylococcal invasive disease.

254 nosin B, is a potent antibiotic with in vivo efficacy against Staphylococcus aureus and Streptococcus

255 erate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infec

256 Their in vitro and in vivo efficacy against strain 536 and a ventilator-associated

257 adducts of various lengths were examined for efficacy against strains of influenza A including those

258 r primary objective was to assess protective efficacy against symptomatic, virologically confirmed de

259 The primary outcome was vaccine efficacy against symptomatic, virologically confirmed de

260 ografts, PR-104 showed significantly greater efficacy against T-lineage ALL (T-ALL) than B-cell-precu

261 zole or mebendazole, but both drugs show low efficacy against T. trichiura.

262 on, compound 2 displayed significant in vivo efficacy against T315I-Bcr-Abl without appreciable toxic

263 as ricin, have been used, aiming for higher efficacy against target cells.

264 urvivin as a self-TAA had potent therapeutic efficacy against TC-1 cervical and 3LL lung carcinoma tu

265 develop additional agents that have improved efficacies against the existent resistant mutants.

266 to prevent acquisition may have differential efficacy against the different modes of transmission.

267 Vaccine efficacy against the first or only episode of clinical m

268 rase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot

269 so known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients

270 The absolute efficacy against the influenza A virus was 72% (95% CI,

271 leu-arg, is tumor-seeking and has antitumor efficacy against the major types of cancer.

272 VEGFR2 and RET, and their antiproliferative efficacy against the medullary thyroid cancer cell line

273 These data show protective efficacy against the most pathogenic Angola strain of MA

274 bial combinations were found to have varying efficacy against the multidrug-resistant bacteria.

275 emonstration of therapeutic anti-Ebola virus efficacy against the new outbreak strain in nonhuman pri

276 ut with emerging viral resistance and little efficacy against the oncogenic herpesviruses, there is a

277 te that the ROS1-selective inhibitors retain efficacy against the recently reported CD74-ROS1(G2032R)

278 iments are frequently used to determine drug efficacy against the survival and proliferation of cance

279 They appear to have efficacy against the symptoms of dry eye that many patie

280 mor targeting selectivity, while the overall efficacy against the targeted tumor was not substantiall

281 substantially improve whooping cough vaccine efficacy against this pathogen.

282 I mutant human Bcr-Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bo

283 lavirus neutralizing activity and protective efficacy against three virulent ebolaviruses.

284 P and elicited protective (43%) and TB (82%) efficacies against transgenic P. berghei parasites expre

285 n with ivermectin would ensure improved drug efficacies against trichuriasis and strongyloidiasis.

286 study, we used autophagy to enhance vaccine efficacy against tuberculosis in a mouse model.

287 combination but not alone, achieved the same efficacy against tumors as the complete parental virus l

288 utic agents because of their selectivity and efficacy against tumors resistant to conventional therap

289 However, treatment efficacy against two isolates of P. digitatum (thiabenda

290 ant's virulence potential and its protective efficacy against type A and type B strains were investig

291 Pibrentasvir had the highest level of efficacy against variants; viruses with RAS at amino aci

292 tly circulating influenza strains, they lack efficacy against viruses expressing divergent globular h

293 Vaccine efficacy against viruses matching the vaccine at positio

294 of trial viruses revealed increased vaccine efficacy against viruses matching the vaccine strain at

295 val 18% to 66%; P = 0.0036), whereas vaccine efficacy against viruses mismatching the vaccine at posi

296 Vaccine efficacy against viruses with a lysine residue at site 1

297 pitope on gp120, displayed a 72-fold reduced efficacy against VS-mediated inocula compared to cell-fr

298 d antibody responses, and reduced protective efficacy against wild-type virus challenge following vac

299 trains is greater than 0.2 but less than the efficacy against wild-type.

300 Curcumin also demonstrated efficacy against ZH501, the fully virulent version of RV